Dude. We're days away from the release of widely expected to be very positive CLINICAL TRIAL DATA on one of the company's THREE drug platforms. This is not the time to focus on every penny of share price movement or incorrect analyses of past events.
Actual shareholders know to have patience, and know the rewards for that patience are soon to come.